Perspectives on Enquiry & Evidence
FDA Increases Calls for Manufacturers to Ensure Trial Diversity, but Does It Fall Short of Addressing Health Inequalities in Product Development?
The evidence is staggering on the unequal health burdens experienced by specific patient groups defined by ethnic, gender, or socioeconomic risk factors and the different health outcomes these groups may have in clinical trials. And while efforts have been made to address these inequalities, they are still falling short.
Webinar: A Clinician’s Perspective on Cancer Drugs Development
A Clinician’s Perspective on Cancer Drugs Development
Interview: Clinical Trial Optimization with R
The Cytel Story: In the Co-Founders' Own Words
Accelerating development with combined SAD/MAD approach
How to get the regulatory green light for your adaptive design?
Blinded SSR in early phase biosimilar studies
Decision Making in Early Clinical Development
Using Simulation for Accelerated Early Phase Drug Development
Dose-finding with Sequential Parallel Comparison Designs
Cultivating Versatility in Statistical Consultants
7 Reasons to Add a Statistical Consultant to Your Team
You Own This!
Part II: The Philosophy Behind a Software Package
5 times ‘Keep it Simple’ May Be Bad Advice for Clinical Designers
10 Simple Steps to Deciding Whether Your Next Trial Should be Adaptive
Frequentist? Time for an update!
New JAMA Study Confirms Importance of Trial Design for FDA Approval
Subscribe to our weekly newsletter
By submitting you agree to Cytel’s Privacy Notice